branaplam

E567204

Branaplam is an investigational small-molecule splicing modulator originally developed for spinal muscular atrophy that enhances SMN protein production by altering SMN2 pre-mRNA splicing.

All labels observed (1)

Label Occurrences
branaplam canonical 1

How this entity was disambiguated

Statements (30)

Predicate Object
instanceOf investigational medicinal product ⓘ
orally bioavailable compound ⓘ
small-molecule drug ⓘ
splicing modulator ⓘ
actsOn SMN2 pre-mRNA ⓘ
administrationForm oral solution ⓘ
affectsBiologicalProcess RNA splicing ⓘ
SMN2 exon inclusion ⓘ
affectsGene SMN2 ⓘ
alsoKnownAs LMI070 ⓘ
NVS-SM1 ⓘ
developedBy Novartis ⓘ
developedFor spinal muscular atrophy ⓘ
drugClass RNA splicing modulator ⓘ
SMN2 splicing modifier ⓘ
hasClinicalTrialPhase Phase 1 ⓘ
Phase 2 ⓘ
increases SMN protein levels ⓘ
indication spinal muscular atrophy type 1 ⓘ
intendedEffect increase functional SMN protein from SMN2 gene ⓘ
mechanismOfAction enhancement of SMN protein production ⓘ
modulation of pre-mRNA splicing ⓘ
molecularTarget SMN2 pre-mRNA splicing ⓘ
relatedToDisease spinal muscular atrophy ⓘ
routeOfAdministration oral ⓘ
status investigational ⓘ
targetPopulation pediatric patients with spinal muscular atrophy ⓘ
therapeuticArea neuromuscular disorders ⓘ
rare diseases ⓘ
therapeuticIntent treatment of spinal muscular atrophy ⓘ

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

SMN2 → targetOfDrug → branaplam ⓘ